Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026)

Axsome Therapeutics has disclosed Gross Margin across 5 years of filings, most recently posting 92.3% for Q1 2026.

• Gross Margin for Q1 2026 came in at 92.3%, up 36.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 92.6% (up 432.0% YoY), and the FY2025 annual result was 92.56%, up 120.0% from the prior year.
• Gross Margin came in at 92.3% for Q1 2026 at Axsome Therapeutics, down from 93.71% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 93.71% in Q4 2025 to a low of 2002.8% in Q4 2024.
• The 5-year median for Gross Margin is 90.9% (2025), against an average of 39.87%.
• Across the five-year window, Gross Margin tumbled 209249 bps in 2024 and soared 209651 bps in 2025, its largest moves.
• Axsome Therapeutics' Gross Margin stood at 90.6% in 2022, then dropped by 1 bps to 89.69% in 2023, then tumbled by 2333 bps to 2002.8% in 2024, then surged by 105 bps to 93.71% in 2025, then fell by 2 bps to 92.3% in 2026.
• The last three Gross Margin figures came in at 92.3% (Q1 2026), 93.71% (Q4 2025), and 93.03% (Q3 2025), per Business Quant data.